X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.120
-0.050 (-1.58%)
Nov 13, 2026, 4:00 PM EST - Market closed
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 45 employees as of December 31, 2025. The number of employees decreased by 98 or 68.53% compared to the previous year. That makes X4 Pharmaceuticals the 35,578th largest employer in the world and 4,788th in the United States.
Employees
45
Change (1Y)
-98
Growth (1Y)
-68.53%
Revenue / Employee
$376,911
Profits / Employee
-$1,789,356
Market Cap
318.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 45 | -98 | -68.53% |
| Dec 31, 2024 | 143 | 50 | 53.76% |
| Dec 31, 2023 | 93 | 23 | 32.86% |
| Dec 31, 2022 | 70 | -13 | -15.66% |
| Dec 31, 2021 | 83 | 11 | 15.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| ProKidney | 231 |
| Kyverna Therapeutics | 149 |
| Enanta Pharmaceuticals | 120 |
| Ocugen | 116 |
| Scribe Therapeutics | 82 |
| Agenus | 81 |
| Atea Pharmaceuticals | 55 |
XFOR News
- 1 day ago - X4 Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 3 days ago - X4 Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - X4 Pharmaceuticals reports Q3 EPS (16c), consensus (19c) - TheFly
- 9 days ago - X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - X4 Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 9 days ago - X4 Pharmaceuticals Earnings release: Q3 2026 - Filings
- 10 days ago - X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026 - GlobeNewsWire
- 15 days ago - X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day - GlobeNewsWire